PALO ALTO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that five clinical and preclinical abstracts have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2008, which will be held in New Orleans, LA on November 8 - 12, 2008.
In addition, company chairman and chief executive officer Louis G. Lange, M.D., PhD. will present The Industry's Perspective on the Pressures, Challenges and Ethics of Conducting Clinical Trials in the Modern Era at an AHA plenary session on November 12, 2008, 9:00 a.m. CST.
The accepted abstracts relate to several different topics, as follows:
Ranexa(R) (ranolazine extended-release tablets):
Ranolazine, a Late Sodium Current Inhibitor, as an Adjunct to Cardioplegia Further Reduces Contracture During Ischemia And Reperfusion; Poster Presentation, Monday, November 10, 2008, 3:00 p.m. CST
Lexiscan(R) (regadenoson) injection
High Reproducibility of Serial Adenosine Single Photon Tomography Myocardial Perfusion Studies: A Quantitative Analysis from the ADVANCE 2 Study; Poster Presentation, Sunday, November 9, 2008, 9:30 a.m. CST
Regadenoson Induces Perfusion Defects of Comparable Extent and Severity as Adenosine: A Quantitative Analysis from the ADVANCE 2 Trial; Oral Presentation, Wednesday, November 12, 2008, 4:15 p.m. CST
Long-Term Morbidity and Mortality among Patients with Angina and Multivessel Coronary Artery Disease in the Duke Cardiovascular Databank; Oral Presentation, Tuesday, November 11, 2008, 9:00 a.m. CST
Late Sodium Current
Discordant T Wave and Mechanical Alternans in Left Ventricular
Hypertrophy: Role of Late Sodium Current;
|SOURCE CV Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved